Trastuzumab related cardiomyopathy. Left ventricular failure
Conditions
Interventions
Intervention 1: Intervention group: Carvedilol drug with 3.125 mg twice daily and then increasing the dose weekly up to 12.5 mg or up to the tolerance. Intervention 2: Control group: Not taking Carved
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have recently been diagnosed with breast cancer (HER2-overexpressing) (stage I to IIIA) and are candidates for adjuvant treatment with trastuzumab. The ability to have an informed consent.
Exclusion criteria
Exclusion criteria: Left Ventricular Ejection Fraction (LVEF) baseline less than 50%, history of heart failure. Contraindication of treatment with or receiving drugs for beta blocker(BB). cardiomyopathy or valvular heart disease, myocardial infarction, uncontrolled blood pressure. history of radiotherapy or chest chemotherapy to the chest. filtration Glomerular volume 30 mL / min / 1.73 m2, which is calculated using the Modification of Diet in Renal Disease (MDRD)method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction. Timepoint: The end of the anthracycline chemotherapy and then the end of sessions 4, 8, 12 and one month after the end of Herceptin. Method of measurement: Echocardiography.;Metastasis. Timepoint: At the end of follow up. Method of measurement: ???????????. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina naderi
Tehran University of Medical Sciences
Outcome results
None listed